First global GERD definition published

13 August 2006

A consensus group of the world's leading experts in gastroenterology has published the first globally-developed definition of gastroesophageal reflux disease. The framework, published in the August issue of the American Journal of Gastroenterology, is intended to provide a universal international platform for this common disease, aiming to support patient diagnosis and disease management, especially in primary care practice.

The consensus group, comprising 43 experts from 18 countries, developed an evidence-based definition of GERD, stating that this disease is "a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications."

The group's chairman, Nimish Vakil, a professor of the University of Wisconsin School of Medicine, USA, said that the lack of a globally-accepted definition of GERD has led to increasing confusion over its symptoms, resulting in both over- and under-diagnosis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight